Kruppel-like factor 2 (KLF2) (KLF2)

Kruppel-like factor 2 (KLF2), also known as Lung Kruppel-like factor (LKLF), is a zinc-finger transcription factor that serves as a master regulator of vascular endothelial health and immune cell function [1, 4]. It is primarily expressed in vascular endothelial cells, where it is induced by laminar shear stress to promote an anti-inflammatory, anti-thrombotic, and vasodilatory phenotype by upregulating genes like endothelial nitric oxide synthase (eNOS) and thrombomodulin [2, 5]. In the immune system, KLF2 is essential for the maturation and orchestrated trafficking of T-cells, regulating their exit from the thymus and entry into peripheral lymphoid tissues [3]. KLF2 is considered a therapeutic target because its downregulation is associated with the progression of atherosclerosis, chronic inflammation, and certain cancers [2, 4]. Pharmacological agents such as statins (e.g., Atorvastatin) and natural compounds like resveratrol have been shown to exert protective cardiovascular effects by inducing KLF2 mRNA and protein expression [2, 5]. Consequently, KLF2 is a focal point for developing therapies aimed at stabilizing the endothelium and modulating immune responses in cardiovascular and inflammatory diseases [1, 5].

Other names

LKLFLung Kruppel-like factorKruppel-like factor 2

Transcriptional induction and upregulation of KLF2 mRNA and protein expression, often via the inhibition of the Rho/ROCK pathway or activation of SIRT1 [2, 5]